Key result
Perfusion of the Syk inhibitor PRT-060318 over preformed thrombi enhanced thrombus breakdown and reduced thrombus contractile score as early as 3 minutes.
Why the study?
Understanding the pathways involved in the formation and stability of the core and shell regions of a platelet-rich arterial thrombus may lead to new ways to treat arterial thrombosis.
Does Syk inhibition reduce thrombus stability in human platelets under high shear flow?
Population
Preformed human platelet thrombi on collagen or atherosclerotic plaque homogenate at arterial shear
Comparison
Post-perfusion of Syk inhibitor PRT-060318 vs ticagrelor, indomethacin, dasatinib, ibrutinib, or GPVI nanobody Nb21
Design
In vitro flow-based assay
Authors
Loading...
May destabilize preformed arterial thrombi; hypothesis-generating for Syk inhibition in human high-shear thrombosis.
Does Syk inhibition reduce thrombus stability in human platelets under high shear flow?
Syk regulates arterial thrombus stability in the absence of fibrin, suggesting Syk inhibition as a potential novel pathway to treat arterial thrombosis.
Perrella et al. (2022) studied Arterial thrombosis. Syk inhibitor PRT-060318 was evaluated on Thrombus stability and contractile score. Perfusion of the Syk inhibitor PRT-060318 over preformed thrombi enhanced thrombus breakdown and reduced thrombus contractile score as early as 3 minutes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: